$1.97
Value $63M
IMDX and UNH stock compared: price, dividend, valuation and results, from SEC filings.
$1.97
Value $63M
$339.85
Value $308B
Insight Molecular Diagnostics (IMDX) has a market value of $63M and UnitedHealth (UNH) $308B. Over the last year, with dividends, IMDX moved -67.2% and UNH +12.9%. Dividend yield: IMDX none, UNH 2.67%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
IMDX$63M
UNH$308B
UNH is 4,868 times IMDX
Revenue, 12 months
IMDX$2.0M
UNH$450B
UNH is 228,371 times IMDX
Net income, 12 months
IMDX-$42M
UNH$15.9B
Operating margin
IMDX-2,180.1%
UNH5.3%
2,185.4 points apart
ROIC
IMDX–
UNH11.3%
P/E
IMDX–
UNH19.4
Dividend yield
IMDX0.0%
UNH2.7%
2.7 points apart
5-year return
IMDX-96.4%
UNH-15.4%
81.0 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
IMDX-96.4%
UNH-15.4%
| Period | IMDXWith dividends | UNHWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -67.2%Price -67.2% | +12.9%Price +10.0% |
| 3 years since November 20, 2023 | -50.3%-20.8% a yearPrice -50.3% | -32.4%-12.2% a yearPrice -36.5% |
| 5 years since November 19, 2021 | -96.4%-48.7% a yearPrice -96.4% | -15.4%-3.3% a yearPrice -22.8% |
| 10 years since November 22, 2016 | -98.3%-33.4% a yearPrice -98.3% | +163.6%+10.2% a yearPrice +123.2% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
IMDXInsight Molecular DiagnosticsUNHUnitedHealth
| Price | $1.97 | $339.85 |
|---|---|---|
| Market value | $63M | $308B |
| Enterprise value (EV) | $53M | $354B |
| P/E | – | 19.4 |
| P/E, 5-year median | – | 25.0 |
| P/B | – | 3.0 |
| EV/EBIT | – | 14.8 |
| Free cash flow yield | – | 7.4% |
| Revenue, 12 months | $2.0M | $450B |
|---|---|---|
| Net income, 12 months | -$42M | $15.9B |
| Free cash flow, 12 months | -$33M | $22.8B |
| Earnings per share, 12 months | -$1.27 | $17.52 |
| Revenue growth, year on year | 115.6% | 11.8% |
| Revenue growth a year, past | +27.2%over 5 years | +11.7%over 5 years |
| EPS growth a year, past | – | -3.8%over 5 years |
| Gross margin | 55.3% | 88.3% |
|---|---|---|
| Operating margin | -2,180.1% | 5.3% |
| Net margin | -2,137.3% | 3.5% |
| ROIC | – | 11.3% |
| ROE | – | 15.5% |
| Cash | $11M | $28.5B |
|---|---|---|
| Total debt | $2.0M | $74.3B |
| Net debt / EBITDA | – | 1.6 |
| Interest cover | – | 6.2× |
| Dividend yield | – | 2.7% |
|---|---|---|
| Dividend per share, 12 months | – | $9.06 |
| Dividend growth a year, past | – | +12.6%over 5 years |
| Buyback yield | – | 1.8% |
| Shareholder yield | – | 4.5% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, UnitedHealth ($308B) is about 4,867.7 times Insight Molecular Diagnostics ($63M), at today's prices.
Since November 22, 2016, IMDX's price moved -98.3% and UNH's +123.2%. With dividends: IMDX -98.3% (-33.4% a year), UNH +163.6% (+10.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Insight Molecular Diagnostics and 2.67% for UnitedHealth. Over the last twelve months they paid – and $9.06 per share.
Over the last twelve months, the net margin was -2,137.3% for Insight Molecular Diagnostics and 3.5% for UnitedHealth, and the operating margin -2,180.1% and 5.3%. Revenue was $2.0M and $450B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.